OSE Immunotherapeutics Announces H1 2021 Results and Provides a Corporate Update
21. September 2021 12:00 ET
|
OSE Immunotherapeutics
Positive final Phase 3 results for Tedopi® in non-small cell lung cancer (NSCLC) after ICI failure.Positive Phase 1 dose escalation results for BI 765063 (CD47/SIRPα pathway) as monotherapy or in...
OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial in Secondary Resistant Non-Small Cell Lung Cancer Patients at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
20. September 2021 07:45 ET
|
OSE Immunotherapeutics
NANTES, France, Sept. 20, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that the positive final results of its Phase 3 trial of neoepitope-based...
OSE Immunotherapeutics To Present Positive Results of Tedopi® Phase 3 Clinical Trial in Non-Small Cell Lung Cancer Patients in Secondary Resistance to Immune Checkpoint Inhibitors At the European Society for Medical Oncology (ESMO) Virtual Congress 2021
20. September 2021 01:30 ET
|
OSE Immunotherapeutics
NANTES, France, Sept. 20, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) announces the presentation of Phase 3 clinical results of Tedopi® today at 13:30 CEST in a...
Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021
16. September 2021 12:00 ET
|
OSE Immunotherapeutics
BI 765063, a first-in-class SIRPα inhibitor in the SIRPα/CD47 “Don’t eat me” pathway, is being developed under collaborative agreement between OSE Immunotherapeutics and Boehringer Ingelheim.Data from...
Boehringer Ingelheim and OSE Immunotherapeutics to Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021
13. September 2021 01:30 ET
|
OSE Immunotherapeutics
BI 765063, a first-in-class SIRPα inhibitor in the SIRPα/CD47 “Don’t eat me” pathway, is being developed under collaborative agreement between OSE Immunotherapeutics and Boehringer Ingelheim. ...
OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Tedopi®
07. September 2021 01:30 ET
|
OSE Immunotherapeutics
Further Strengthens Global Intellectual Property Portfolio for Tedopi®in Non-Small Cell Lung Cancer until 2035 NANTES, France, Sept. 07, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN:...
OSE Immunotherapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
01. September 2021 12:00 ET
|
OSE Immunotherapeutics
NANTES, France, Sept. 01, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173) today announced it will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The...
OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer
26. August 2021 12:00 ET
|
OSE Immunotherapeutics
Clinical trial sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by Merck Sharp & Dohme Corp. (MSD), a subsidiary of Merck & Co., Inc., Kenilworth,...
Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome
25. August 2021 12:00 ET
|
OSE Immunotherapeutics
PARIS and NANTES, France, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), a French biotech,...
OSE Immunotherapeutics Announces Upcoming Investor Conferences and R&D Day
24. August 2021 12:00 ET
|
OSE Immunotherapeutics
NANTES, France, Aug. 24, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that the Company will be present at the following investor events: H.C....